共 90 条
[1]
Amin J(2015)Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD Inflamm Bowel Dis 21 445-452
[2]
Huang B(2015)Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine Inflamm Bowel Dis 21 1054-1062
[3]
Yoon J(2012)Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis Cochrane Database Syst Rev. 9 CD000478-567
[4]
Lee MN(2004)Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease Pharmacoepidemiol Drug Saf 13 563-652
[5]
Kang B(2007)Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease Aliment Pharmacol Ther 26 643-1800
[6]
Choi SY(2008)Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review Am J Gastroenterol 103 1783-1264
[7]
Timmer A(2009)Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease J Gastroenterol Hepatol 24 1258-227
[8]
McDonald JW(2008)Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease Aliment Pharmacol Ther 27 220-1077
[9]
Tsoulis DJ(2007)Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease Aliment Pharmacol Ther 25 1069-50
[10]
Gearry RB(2006)Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease Ther Drug Monit 28 45-77